Diligence memo · auto-generated · as of July 3, 2026

Hastings Medical Imaging, LLC

Hastings Medical Imaging, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Hastings Medical Imaging, LLC operates in Hospitals and Physicians, based in HASTINGS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Hastings Medical Imaging, LLC has raised $1.1M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $816K on 2022-01-01.

Most recent recorded round closed around 2022-01-01.

Valuation (modeled)modeled

Provath models Hastings Medical Imaging, LLC at approximately $11M (range $533K–$82M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.99× the median modeled value of Pre-Seed Hospitals and Physicians companies in 2022–2024 (15 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 10 months.

Last raise 4.5 yr ago; this sector typically re-raises about every 12 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 2.9× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 39% of Hospitals and Physicians peers (599 compared).

Modeled value ranks above 34% of those peers.

Closest niche peers: Binghamton Project, LLC, VitalSkin Holdings, LLC, IMS Holdings of Arizona, LLC, Millennium Asc, Llc, Clarence Health Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.